Israeli-based Teva Pharmaceutical Industries announced Monday it will invest $50 million for a new Czech unit. The investment was revealed during Czech Prime Minister Mirek Topolanek's visit. Last week, Teva said it will invest another $50 million in its facility in Ireland.

Teva is a world leader in the manufacture of generic drugs, which will be produced at the Czech plant and sold worldwide. Eight percent of Teva's employees are located in Central and Eastern Europe.